GS-US-563-5925: People With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir

CONDITION

Other

GENDER

All

AGE GROUP

From 18

and above

STATUS

Active, not recruiting

A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir (B/F/TAF)

Studies Contact Form

  • This field is hidden when viewing the form

Approved By: Bellberry limited              

Clinical Trial Registry Link: